Hypertonie bei Dialysepatienten

 

 Buy Article Permissions and Reprints

ZUSAMMENFASSUNG

Die Hypertonie bei Dialysepatienten ist eine besondere Herausforderung, die zuletzt durch eine uneinheitliche Definition verkompliziert wurde. Eine optimale Hypertoniekontrolle wird bisher nur bei wenigen Patienten erreicht. Therapeutisch sollten primär nicht pharmakologische Maßnahmen ergriffen werden, hierbei dient der Salz- und Volumenstatus als zentraler und fundamentaler Angriffspunkt. Eine medikamentöse Therapie scheint sich positiv auf die kardiovaskuläre Prognose auszuwirken; eine überlegene Substanz als primäre Wahl konnte jedoch bisher noch nicht eindeutig identifiziert werden. Zukünftig braucht es mehr Studien, um Ziel-Blutdruck-Werte festlegen zu können und die Wirksamkeit von nicht medikamentösen und medikamentösen Maßnahmen hinsichtlich der kardiovaskulären Prognose zu überprüfen.

• Literatur

• 1 Sarafidis PA, Persu A, Agarwal R. et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). Nephrol Dial Transplant 2017; 32: 620-640 doi:10.1093/ndt/gfw433
  CrossrefPubMedGoogle Scholar
• 2 Siu AL. U. S. Preventive Services Task Force. Screening for high blood pressure in adults: U. S. Preventive Services Task Force recommendation statement. Ann Intern Med 2015; 163: 778-786 doi:10.7326/M15-2223
  CrossrefPubMedGoogle Scholar
• 3 Agarwal R, Light RP. Chronobiology of arterial hypertension in hemodialysis patients: implications for home blood pressure monitoring. Am J Kidney Dis 2009; 54: 693-701 doi:10.1053/j.ajkd.2009.03.018
  CrossrefPubMedGoogle Scholar
• 4 Agarwal R, Andersen MJ, Light RP. Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients. Am J Nephrol 2008; 28: 210-217 doi:10.1159/000110090
  CrossrefPubMedGoogle Scholar
• 5 Kidney Disease Outcomes Quality Initiative (K/DOQI) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (Suppl. 01) S1-S290
  PubMedGoogle Scholar
• 6 Agarwal R, Peixoto AJ, Santos SF, Zoccali C. Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol 2006; 1: 389-398 doi:10.2215/CJN.01891105
  CrossrefPubMedGoogle Scholar
• 7 Kelley K, Light RP, Agarwal R. Trended cosinor change model for analyzing hemodynamic rhythm patterns in hemodialysis patients. Hypertension, 2007; 50: 143-150 doi:10.1161/HYPERTENSIONAHA.107.091579
  CrossrefPubMedGoogle Scholar
• 8 Zucchelli P, Santoro A, Zuccala A. Genesis and control of hypertension in hemodialysis patients. Semin Nephrol 1988; 8: 163-168
  PubMedGoogle Scholar
• 9 Günal AI, Duman S, Ozkahya M. et al. Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis 2001; 37: 588-593
  CrossrefPubMedGoogle Scholar
• 10 Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009; 53: 500-507 doi:10.1161/HYPERTENSIONAHA.108.125674
  CrossrefPubMedGoogle Scholar
• 11 Dahlmann A, Dorfelt K, Eicher F. et al. Magnetic resonance-determined sodium removal from tissue stores in hemodialysis patients. Kidney Int 2015; 87: 434-441 doi:10.1038/ki.2014.269
  CrossrefPubMedGoogle Scholar
• 12 Agarwal R, Light RP. Arterial stiffness and interdialytic weight gain influence ambulatory blood pressure patterns in hemodialysis patients. Am J Physiol Renal Physiol 2008; 294: F303-F308 doi:10.1152/ajprenal.00575.2007
  CrossrefPubMedGoogle Scholar
• 13 Georgianos PI, Sarafidis PA, Lasaridis AN. Arterial stiffness: a novel cardiovascular risk factor in kidney disease patients. Curr Vasc Pharmacol 2015; 13: 229-238
  CrossrefPubMedGoogle Scholar
• 14 Daugirdas JT, Blake PG, Ing TS. Handbook of dialysis. 5th ed. Philadelphia: Wolters Kluwer Health; 2015
  Google Scholar
• 15 Hausberg M, Kosch M, Harmelink P. et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-1979
  CrossrefPubMedGoogle Scholar
• 16 Tada T, Kusano KF, Ogawa A. et al. The predictors of central and obstructive sleep apnoea in haemodialysis patients. Nephrol Dial Transplant, 2007; 22: 1190-1197 doi:10.1093/ndt/gfl748
  CrossrefPubMedGoogle Scholar
• 17 Kornerup HJ, Schmitz O, Danielsen H. et al. Significance of the renin-angiotensin system for blood pressure regulation in end-stage renal disease. Contrib Nephrol 1984; 41: 123-127
  PubMedGoogle Scholar
• 18 Henrich WL, Katz FH, Molinoff PB, Schrier RW. Competitive effects of hypokalemia and volume depletion on plasma renin activity, aldosterone and catecholamine concentrations in hemodialysis patients. Kidney Int 1977; 12: 279-284
  CrossrefPubMedGoogle Scholar
• 19 Vallance P, Leone A, Calver A. et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575
  CrossrefPubMedGoogle Scholar
• 20 Del Vecchio L, Locatelli F. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease. Expert Opin Drug Saf 2016; 15: 1021-1030 doi:10.1080/14740338.2016.1182494
  CrossrefPubMedGoogle Scholar
• 21 Smyth B, Jones C, Saunders J. Prescribing for patients on dialysis. Aust Prescr 2016; 39: 21-24 doi:10.18773/austprescr.2016.008
  CrossrefPubMedGoogle Scholar
• 22 George J, Majeed W, Mackenzie IS. et al. Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study. BMJ 2013; 347: f6954 doi:10.1136/bmj.f6954
  CrossrefPubMedGoogle Scholar
• 23 Sarafidis PA, Sharpe CC, Wood E. et al. Prevalence, patterns of treatment, and control of hypertension in predialysis patients with chronic kidney disease. Nephron Clin Pract 2012; 120: c147-c155 doi:10.1159/000337571
  CrossrefPubMedGoogle Scholar
• 24 Agarwal R, Nissenson AR, Batlle D. et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115: 291-297
  CrossrefPubMedGoogle Scholar
• 25 Agarwal R. Epidemiology of interdialytic ambulatory hypertension and the role of volume excess. Am J Nephrol 2011; 34: 381-390 doi:10.1159/000331067
  CrossrefPubMedGoogle Scholar
• 26 Takeda A, Toda T, Fujii T. et al. Discordance of influence of hypertension on mortality and cardiovascular risk in hemodialysis patients. Am J Kidney Dis 2005; 45: 112-118
  CrossrefPubMedGoogle Scholar
• 27 Heerspink HJ, Ninomiya T, Zoungas S. et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373: 1009-1015 doi:10.1016/S0140-6736(09)60212-9
  CrossrefPubMedGoogle Scholar
• 28 Foley RN, Parfrey PS, Kent GM. et al. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000; 11: 912-916
  PubMedGoogle Scholar
• 29 Agarwal R. How should hypertension be assessed and managed in hemodialysis patients? Home BP, not dialysis unit BP, should be used for managing hypertension. Semin Dial 2007; 20: 402-405 doi:10.1111/j.1525-139X.2007.00314.x
  CrossrefPubMedGoogle Scholar
• 30 Stack AG, Molony DA, Rives T. et al. Association of physical activity with mortality in the US dialysis population. Am J Kidney Dis 2005; 45: 690-701
  CrossrefPubMedGoogle Scholar
• 31 Sinha AD, Agarwal R. Can chronic volume overload be recognized and prevented in hemodialysis patients? The pitfalls of the clinical examination in assessing volume status. Semin Dial 2009; 22: 480-482 doi:10.1111/j.1525-139X.2009.00641.x
  CrossrefPubMedGoogle Scholar
• 32 Raimann J, Liu L, Tyagi S. et al. A fresh look at dry weight. Hemodial Int 2008; 12: 395-405 doi:10.1111/j.1542-4758.2008.00302.x
  CrossrefPubMedGoogle Scholar
• 33 Movilli E, Gaggia P, Zubani R. et al. Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study. Nephrol Dial Transplant 2007; 22: 3547-3552 doi:10.1093/ndt/gfm466
  CrossrefPubMedGoogle Scholar
• 34 Agarwal R, Sinha AD, Pappas MK. et al. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant 2014; 29: 672-681 doi:10.1093/ndt/gft515
  CrossrefPubMedGoogle Scholar
• 35 Cice G, Ferrara L, D’Andrea A. et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. Journal of the American College of Cardiology 2003; 41: 1438-1444
  CrossrefPubMedGoogle Scholar
• 36 Tepel M, Hopfenmueller W, Scholze A. et al. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant, 2008; 23: 3605-3612 doi:10.1093/ndt/gfn304
  CrossrefPubMedGoogle Scholar
• 37 Kungys G, Naujoks H, Wanner C. Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. Eur J Clin Pharmacol 2003; 59: 291-295 doi:10.1007/s00228-003-0620-4
  CrossrefPubMedGoogle Scholar
• 38 Weir MA, Fleet JL, Dixon SN. et al. Angiotensin Converting Enzyme Inhibitor Dialyzability and Outcomes in Older Patients Receiving Hemodialysis. Blood Purif, 2015; 40: 232-242 doi:10.1159/000438821
  CrossrefPubMedGoogle Scholar
• 39 Weir MA, Dixon SN, Fleet JL. et al. β-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol 2015; 26: 987-996 doi:10.1681/ASN.2014040324
  CrossrefPubMedGoogle Scholar